The multiomics for precision medicine market is valued at USD 1,707.5 million in 2025 and is projected to reach USD 7,014.8 million by 2034, growing at a CAGR of 17.0% from 2026 to 2034. Polaris Market Research links this expansion to three interconnected spending needs: generating additional molecular layers, integrating them with clinical information, and interpreting results to support a defined drug-development decision. The 2026 estimate is USD 1,991.6 million.

Resolution and Protein Measurement

Bulk multiomics holds the largest technology size at USD 1,053 million in 2025 because it suits cohort-scale studies. Spatial multiomics is projected to grow fastest at a CAGR of 17.46%, ahead of bulk and single-cell approaches. Together with single-cell analysis, it moves measurement from averaged tissue to individual cells and their spatial relationships, revealing cellular heterogeneity, resistant populations, and immune states.

NGS-based proteomics shows how protein measurement is joining sequencing infrastructure. Illumina's SomaSeq Discovery workflow measures 9,500 human protein targets, and the proteomics segment is projected to grow at a CAGR of 16.4%.

Illumina's 5-base workflow, launched in October 2025, combines genomic variation and methylation in a single workflow. NIH data releases also identified 275 million previously unreported genetic variants from nearly 250,000 participants, and later releases expanded the All of Us resource to 1.3 billion genetic variants.

Components and Omics Types

Consumables are the largest component, valued at USD 512.1 million in 2025 and growing at a CAGR of 17.3%, because reagents, kits, and assay consumables create recurring per-sample spend. Instruments are the fastest-growing component at 17.72%. Genomics leads the omics-type segment with USD 693.9 million and a 40.64% share in 2025.

Transcriptomics, proteomics, metabolomics, and epigenomics add information on gene expression, functional signals, downstream biochemical states, and regulatory changes around the stable genomic reference layer.

Rare Disease and Hospital Adoption

Rare disease diagnostics is a growing opportunity, with rare disease applications expanding at a CAGR of 17.7%. Multiomic evidence can help resolve uncertain variants and connect genomic findings with RNA or protein-level effects. Hospitals and clinical laboratories are expected to grow at 16.1% as the approach moves closer to clinical decision-making, though these buyers require stronger validation and faster turnaround.

Metabolon also launched its Peak Science Grant Program in August 2026, giving researchers access to metabolomics analysis, bioinformatics tools, and scientific expertise.

Browse In-depth Market Research Report:

https://www.polarismarketresearch.com/industry-analysis/multiomics-for-precision-medicine-market 

Regulation and Regional Outlook

The European Health Data Space, established under Regulation (EU) 2025/327, entered into force in March 2025, with secondary-use provisions applying in stages from 2029 and genomic data provisions from 2031. Europe is the second-largest market, estimated at USD 477.7 million in 2025. Asia Pacific is projected to register the fastest CAGR of 17.6%, although China's human genetic resource and data controls influence cross-border projects.

Japan emphasizes regulated clinical evidence, Singapore functions as a concentrated research and biopharma hub, and India's opportunity is linked to population diversity and expanding hospital networks. Latin America is growing steadily through Brazil and Mexico, where population diversity supports ancestry-aware precision models even though fragmented records and variable reimbursement restrict routine clinical use. In the Middle East and Africa, Saudi Arabia, the UAE, Qatar, and South Africa are developing genomics and digital-health capabilities.

Key Players

Major participants in the market include:

• Agilent Technologies, Inc.
• BD (Becton, Dickinson and Company)
• Bio-Techne Corporation
• Bruker Corporation
• Hoffmann-La Roche Ltd
• Illumina, Inc.
• io, Inc.
• Oxford Nanopore Technologies plc
• Psomagen, Inc.
• QIAGEN N.V.
• SOPHiA GENETICS SA
• Tempus AI, Inc.
• Thermo Fisher Scientific Inc.
• 10x Genomics, Inc.

Conclusion

To summarize, the multiomics for precision medicine market is broadening beyond sequencing volume toward higher-resolution measurement, protein depth, and governed data reuse. Consumables provide recurring demand, instruments are expanding capacity, and regulation is shaping how data is accessed across regions. Vendors that combine technical depth with compliance readiness are best placed for growth through 2034.

More Trending Latest Reports By Polaris Market Research:

Automotive Collision Repair Market

Automotive Engineering Services Market

Regenerative Meat Market

Lewy Body Dementia Treatment Market

DNA Diagnostics Market

Neurovascular Intervention Devices Market

Neurovascular Intervention Devices Market

Regenerative Meat Market

Healthcare Predictive Analytics Market